Navigation and service

Projects "Go-Bio"

Towards a vaccine for chronic infectious agents : Date:

GO-Bio 4 – Prof. Dr. Markus Gerhard – Institute for Medical Microbiology, Technical University of Munich | ImevaX GmbH

New therapies on the basis of RNA molecules : Date:

GO-Bio 3 – Prof. Dr. Gunther Hartmann – Institute of Clinical Chemistry and Pharmacology, University Hospital Bonn

Using biochips to analyse cell networks and test active substances : Date:

GO-Bio 3 – Philipp Julian Köster – Department of Biophysics, University of Rostock

Genetic vaccines: New platform technology for improved efficacy : Date:

GO-Bio 3 – Dr. Florian Kreppel – Department of Gene Therapy, University of Ulm

Multi-organ bioreactor in chip format : Date:

GO-Bio 3 – Prof. Roland Lauster, Dr. Uwe Marx – Chair of Medical Biotechnology, Technical University Berlin | TissUse GmbH

Hearing the light from the body – the next generation of imaging : Date:

GO-Bio 3 – Prof. Vasilis Ntziachristos, Christian Wiest – Institute for Biological and Medical Imaging (IBMI), Helmholtz Center Munich | iThera Medical GmbH

Immunotherapy to combat the hospital bug Staphylococcus aureus : Date:

GO-Bio 3 – PD Dr. Knut Ohlsen – Institute for Molecular Infection Biology (IMIB), University of Würzburg

Equipping potatoes with resistance to fungal infestation : Date:

GO-Bio 2 – Dr. Dieter Peschen – Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen

Development of more effective antibodies against leukaemia and solid tumours : Date:

GO-Bio 2 – Dr. Ludger Große-Hovest, Gundram Jung – Center for Clinical Transfusion Medicine (ZKT), Tübingen; Synimmune GmbH

Production of small RNA molecules for muting long non-coding RNAs : Date:

GO-Bio 2 – Prof. Dr. Frank Buchholz – Dresden University Hospital | Eupheria Biotech GmbH

Tracking down the security guards of the cell: New therapeutic approach for the treatment of cardiovascular diseases : Date:

GO-Bio 2 – PD Dr. Enno Klußmann – Forschungsverbund Berlin e. V.

New active substances for activating or inhibiting AGC protein kinases : Date:

GO-Bio 2 – Dr. Ricardo M. Biondi – Goethe University Frankfurt

A biocatalysis reactor for the industrial-scale production of therapeutic siRNA molecules : Date:

GO-Bio 2 – PD Dr. med. Jacques Rohayem – Technical University Dresden | Riboxx GmbH, Radebeul

Molecular scissors for tackling HIV : Date:

GO-Bio 2 – Prof. Dr. Joachim Hauber – Department of Cell Biology and Virology, Heinrich Pette Institute (HPI) for Experimental Virology and Immunology, Hamburg

Development of a new class of drug for the prevention of organ damage in cardiac insufficiency and diabetes : Date:

GO-Bio 2 – Dr. Heiko Funke-Kaiser – Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité University Medicine Berlin 

Development of a blood purification method for the treatment of patients with acute myocardial infarction : Date:

GO-Bio 2 – Dr. Ahmed Sheriff – Charité University Medicine Berlin, Clinic of Nephrology and Internal Intensive Care Medicine, as well as the Clinic of Cardiology, Campus Virchow Klinikum

Neuroprosthesis for the restoration of mobility in people with severe paralysis : Date:

GO-Bio 1 – Dr. Carsten Mehring – ‘Computational Motor Control & Brain-Machine Interfaces’ working group, Albert Ludwig University of Freiburg

Development of cancer drugs on the basis of highly effective small molecules : Date:

GO-Bio 1 – Joe Lewis, PhD – European Molecular Biology Laboratory (EMBL) and the German Cancer Research Center (DKFZ) at the Helmholtz Association, Heidelberg | Elara Pharmaceuticals GmbH

Development of drugs for the treatment of Huntington’s and Alzheimer's : Date:

GO-Bio 1 – Prof. Dr. Erich Wanker – Max Delbrück Center for Molecular Medicine (MDC), Berlin

New therapeutic approach for the preventive treatment of atherosclerotic diseases : Date:

GO-Bio 1 – PD Dr. Dorothea Siegel-Axel – Department of Cardiology, University Clinic Tübingen | corimmun GmbH

Search results 61 to 80 from a total of 85